Levetiracetam Accord (Levetiracetam)

• Levetiracetam is an antiepileptic drug that reduces neuronal excitability in various seizure types.
• Partial‑onset seizures: reduces the frequency and severity of focal seizure episodes in patients diagnosed with epilepsy, improving daily functioning.
• Myoclonic seizures: effectively controls sudden, brief muscle jerks characteristic of juvenile myoclonic epilepsy, helping to maintain motor stability.
• Primary generalized tonic‑clonic seizures: lowers the occurrence of bilateral convulsive seizures in generalized epilepsy, contributing to overall seizure control.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates vesicle exocytosis, decreasing the release of excitatory glutamate and stabilizing neuronal firing. By reducing synaptic transmission in hyper‑excitable networks, the drug lowers the likelihood of seizure propagation without significant interaction with ion channels or G‑protein‑coupled receptors. The precise downstream effects remain under investigation, but the SV2A binding is considered the primary therapeutic mechanism.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: persistent tiredness affecting daily activities.
• Headache: mild to moderate cranial pain.
• Irritability: mood changes including increased agitation.
• Nausea: upset stomach often occurring after dosing.

Serious or Rare Side Effects

• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts or behavior: emergence of depressive symptoms or self‑harm ideation.
• Multi‑organ hypersensitivity: including fever, rash, eosinophilia, and organ dysfunction.

Before initiating Levetiracetam Accord, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: assess kidney function and adjust dose as recommended.
• Pregnancy: risk category unknown; discuss potential benefits and risks with the patient.
• Psychiatric symptoms: monitor for mood changes, depression, or suicidal ideation.
• Concomitant CNS depressants: may enhance sedation; observe patient response.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Levetiracetam can interact with other medicines, influencing its plasma concentration or enhancing side effects.

Major Interactions (Avoid)

• Carbamazepine: induces metabolism, markedly reducing levetiracetam levels.
• Phenytoin: enzyme induction leading to decreased levetiracetam exposure.
• Phenobarbital: accelerates clearance and may diminish therapeutic effect.

Moderate Interactions (Monitor Closely)

• Alcohol: additive CNS depression may increase dizziness or somnolence.
• Other antiepileptic drugs: combined therapy may require dose adjustments.
• Renal excretion inhibitors: monitor renal function and levetiracetam concentrations.